Background/Aims: Activation of the Wnt/β-catenin signalling pathway has been widely investigated in bone biology and shown to promote bone formation. However, its specific effects on osteoclast differentiation have not been fully elucidated. Our study aimed to identify the role of β-catenin in osteoclastogenesis and bone homeostasis. Methods: In the present study, exon 3 in the β-catenin gene (Ctnnb1) allele encoding phosphorylation target serine/ threonine residues was flanked by floxP sequences. We generated mice exhibiting conditional β-catenin activation (Ctsk-Cre;Ctnnb1 flox(exon3)/+ , designated CA-β-catenin) by crossing Ctnnb1 flox(exon3)/flox(exon3) mice with osteoclast-specific Ctsk-Cre mice. Bone growth and bone mass were analysed by micro-computed tomography (micro-CT) and histomorphometry. To further examine osteoclast activity, osteoclasts were induced from bone marrow monocytes (BMMs) isolated from CA-β-catenin and Control mice in vitro. Osteoclast differentiation was detected by tartrate-resistant acid phosphatase (TRAP) staining, immunofluorescence staining and reverse transcription-quantitative PCR (RT-qPCR) analysis. Results: Growth retardation and low bone mass were observed in CA-β-catenin mice. Compared to controls, CA-β-catenin mice had significantly reduced trabecular bone numbers under growth plates as well as thinner cortical bones. Moreover, increased TRAP-positive osteoclasts were observed on the surfaces of trabecular bones and cortical bones in the CA-β-catenin mice; consistent results were observed in vitro. In the CA-β-catenin group, excessive numbers of osteoclasts were induced from BMMs, accompanied by the increased expression of osteoclast-associated marker genes. Conclusion: These results indicated that the constitutive activation of β-catenin in osteoclasts promotes osteoclast formation, resulting in bone loss.
Constitutive Activation of β-Catenin in
Introduction β-catenin, the centre of canonical Wnt signalling, is essential for bone homeostasis [1] . Knockout or activation of β-catenin at diverse differentiation stages in different bone cells results in distinct phenotypes. For example, β-catenin knockout in mesenchymal stem cells, osteoblasts and osteocytes results in low bone mass, while the constitutive activation of β-catenin in these cells increases bone mass. During the early stages of osteoblast differentiation, knocking out β-catenin in mesenchymal progenitors results in the termination of osteoblast differentiation and abnormal cartilage formation [2] . Thus, β-catenin is necessary for early osteoblast differentiation, and β-catenin deficiency promotes mesenchymal stem cells to differentiate into cartilage cells [3] . Knockout of β-catenin in mature osteoblasts significantly decreases bone mass. Moreover, targeted activation of β-catenin induces osteopetrosis and increases bone mass [4] [5] [6] . With the exception of osteoblasts, β-catenin knockout in osteocytes results in progressive bone loss in the appendicular and axial skeleton, while constitutive activation of β-catenin in osteocytes results in high bone mass. These findings confirm the important effects of Wnt/β-catenin signalling for maintaining bone mass [7, 8] . All these findings revealed that Wnt/β-catenin signalling exerts essential effects on bone formation and bone mass regulation. However, the effects of Wnt/β-catenin signalling on osteoclastogenesis remain unclear.
Osteoclasts, the only bone-resorbing cell type, are derived from the monocyte/ macrophage haematopoietic lineage and play an important role in bone homeostasis [9] . Excessive osteoclastic activity is related to osteoporosis, periodontal disease, osteoarthritis and metastatic cancers [10] . Osteoclast differentiation and activation processes are mainly regulated by receptor activator of nuclear factor-κB ligand (RANKL) signalling [11] . In addition to RANKL, other factors, such as tumour necrosis factor α (TNFα), interleukins (e.g., IL1 and IL6) and factors released from absorbed bone matrix (e.g., TGFβ1 and IGF1), are involved in regulating bone resorption and osteoclastogenesis [12] [13] [14] [15] . However, according to previous studies, Wnt/β-catenin signalling may exert an indirect inhibitory effect on osteoclast differentiation by promoting the expression of osteoprotegerin (OPG) [4, 5, 8, 16, 17] .
It has recently been reported that Wnt/β-catenin signalling has a direct effect on the regulation of osteoclastogenesis. β-catenin deletion in osteoclast progenitors results in osteoporosis in heterozygotes but decreased bone resorption in homozygotes. β-catenin is necessary for early osteoclast proliferation [18] . Knockout of β-catenin during the late stages of osteoclast differentiation results in enhanced osteoclast formation and osteopenia with no effects on OPG in mice [18] [19] [20] [21] . These findings suggest that inactivation of β-catenin in osteoclasts results in low bone mass and that β-catenin plays an important part in osteoclast formation. As mentioned above, activation of β-catenin is critical for osteoblast lineage cell differentiation during bone formation. However, the effects of stabilized β-catenin on osteoclast differentiation remain unclear. Therefore, the present work aimed to confirm that the constitutive activation of β-catenin in osteoclasts plays roles in bone growth, bone mass, and osteoclastogenesis.
The present study investigated the direct functions of β-catenin stabilization in osteoclasts by crossing Ctnnb1 flox(exon3)/flox(exon3) and Ctsk-Cre mice. The generated mice showed a low bone mass phenotype with increased osteoclast formation in vivo and in vitro. Therefore, constitutive activation of β-catenin may promote osteoclastogenesis, which further implicates the pivotal role of β-catenin in maintaining bone homeostasis.
Materials and Methods

Animals
All experimental procedures were approved by the Animal Welfare Committee of Tongji University (Shanghai, China). To determine the role of stabilized β-catenin in osteoclasts, Ctnnb1 flox(exon3)/flox(exon3) mice (C57BL/6J background, Beijing Biocytogen, China) were crossed with osteoclast-specific Ctsk-Cre mice (C57BL/6J background, Beijing Biocytogen, China) [22, 23] . The Ctsk-Cre mice were knock-in mice and used as heterozygotes. Ctsk-Cre;Ctnnb1 flox(exon3)/+ mice (CA-β-catenin, constitutive activation of β-catenin) were the target mice, in which exon 3 of the β-catenin gene (Ctnnb1) in osteoclasts was knocked out to prevent β-catenin destruction. This alteration permitted the accumulation of cytosolic β-catenin, which subsequently translocates into the nucleus to regulate gene expression. Ctnnb1 flox(exon3)/+ (Control) littermates were used as controls. To confirm the site specificity of Ctsk-Cre mice, Rosa26 mT/mG mice were crossed with Ctsk-Cre mice.
Micro-computed tomography (micro-CT) analyses
Dissected femurs from 4-week-old mice were fixed in 4% paraformaldehyde for 48 hours (n = 6 each group). After fixation, the femurs were scanned and analysed by micro-CT-50 (Scanco Medical, Bassersdorf, Switzerland). Micro-CT analysis included a high-resolution scan of the entire femur bone (10-μm slice increments). For cortical bone analysis, a cylindrical area starting from the mid-diaphysis and extending 1000 μm (100 slices) was selected and analysed. For trabecular bone analysis, an area starting from the growth plate in the centre of the metaphysis region with a proximal length of 1000 μm (100 slices) was selected. The following quantitative morphometric analyses were determined: bone volume to total volume ratio (BV/TV), mean trabecular thickness (Tb.Th), trabecular separation (Tb.Sp), trabecular number (Tb.N), and mean cortical thickness (Ct.Th).
Bone histology
After demineralization in 10% EDTA (pH = 7.4), femurs were embedded in paraffin and cut into 4-μm-thick sections. After deparaffinization and rehydration, the histologic characterization of mouse femurs (n = 5 each group) at 4 weeks was performed by haematoxylin-eosin (H&E) staining (Biotech Well, China), immunohistochemistry (IHC) staining (UltraSitive S-P detection kit, MXB, China) and tartrate-resistant acid phosphatase (TRAP) staining (Sigma, USA). The number of TRAP-positive osteoclasts per slice in an entire section was counted in five different sections. The mean number was calculated and used for the statistical analyses [24] .
In vitro osteoclast differentiation and immunofluorescence staining
For in vitro osteoclast differentiation analyses, bone marrow cells were isolated from 4-week-old femurs and tibias of Control and CA-β-catenin mice and cultured for 24 hours with α minimal essential medium (α-MEM) (HyClone, USA) supplemented with 10% foetal bovine serum (FBS) (Gibco, USA) and 1% penicillin (10, 000 IU)-streptomycin (10, 000 mg/mL) (HyClone, USA) as previously described [25, 26] . Non-adherent bone marrow monocytes (BMMs) were harvested and seeded into 24-well plates at a concentration of 5×10 5 cells per well and 6-well plates at a concentration of 3×10 6 cells per well. The cells were cultured with 50 ng/mL mouse macrophage colony stimulating factor (M-CSF) (PeproTech, USA) in α-MEM (HyClone, USA) containing 10% FBS for 1-2 days and then stimulated with 50 ng/mL mouse M-CSF and 100 ng/mL mouse receptor activator of nuclear factor-κB ligand (RANKL) (PeproTech, USA) for 4-6 days. All in vitro experiments were normatively repeated at least 4 times.
For TRAP staining, the cells were fixed in 4% paraformaldehyde and stained using a TRAP staining kit (Sigma, USA). The number of mature osteoclasts per well was counted as multinucleated (>3 nuclei) TRAPpositive cells [19, 27] . RNA expression was analysed by reverse transcription-quantitative PCR (RT-qPCR) analysis. Protein expression was analysed by Western blotting.
For immunofluorescence staining, the cells were fixed in 4% paraformaldehyde for 30 minutes, washed 2-3 times with PBS, permeabilized using 0.1% Triton X-100 in PBS and washed twice with PBS. After blocking, the cells were incubated with anti-β-catenin (Cell Signalling Technology, USA, 9562, 1:500) and anti-cathepsin K (Proteintech, USA, 11239-1-AP, 1:300) antibodies at 4°C overnight or in phalloidin (Sigma, USA, P5282) at 37°C for one hour. The cells were then incubated with secondary antibody (Abcam, USA, 
RT-qPCR analysis
For the RT-qPCR analysis, total RNA was extracted from the femurs of 4-week-old mice using TRIzol (Takara, Japan). cDNA was synthesized by the reverse transcription of total RNA with a Transcription First Strand cDNA Synthesis Kit (Roche, Switzerland). Gene expression was estimated by real-time qPCR. PCR primers for Trap, Traf6, Mmp9, Nfatc1, Calcr, Oscar, Dcstamp, Tcf, Lef-1, Wisp, c-Myc and Gapdh are provided in Table 1 . The expression of each gene was normalized to that of Gapdh, and all experiments were repeated 3 times.
Western blotting
Total protein was extracted from femurs and cells by lysing cells in RIPA lysis buffer (Beyotime, China) supplemented with protease and phosphatase inhibitors. Protein (30 μg per lane) was electrophoresed in a 10% sodium dodecyl sulphate-polyacrylamide (SDS-PAGE) gel and transferred to a polyvinylidene difluoride (PVDF) membrane (Millipore, USA). Membranes were blocked in 5% BSA for 1 hour and then incubated at 4°C overnight with primary antibodies. After three 5-minute washes with TBS-T (0.1% Tween-20), the membranes were incubated with an HRP-conjugated secondary antibody (CWBiotech, China, 1:2000). Target protein was detected using a detection reagent (Immobilon™ Western, Millipore, USA) and visualized by a chemiluminescent imager (ImageQuant LAS 4000mini). Antibodies targeting the following molecules were used: β-catenin (Cell Signalling Technology, USA, 9562, 1:1000), non-phospho (active) β-catenin (Ser33/37/Thr41) (Cell Signalling Technology, USA, 8814, 1:1000), GAPDH (Abways, ab2000, 1:5000) and Lamin B1 (Proteintech, USA, 12987-1-AP, 1:1000). All experiments were normatively repeated at least 3 times.
Statistical analyses
All data are represented as the mean ± standard deviation. Statistical analyses were conducted with SPSS statistics 20 (IBM) using a Student's t-test with statistical significance levels of # P < 0.05, *P < 0.05 and **P < 0.01.
Results
β-catenin expression pattern in osteoclasts
The expression of β-catenin in osteoclasts was detected by immunohistochemistry and immunofluorescence in vivo and in vitro (Fig. 1A-D) . Actin ring formation, which is typical of active osteoclasts, was stained with phalloidin (green fluorescence). β-catenin was located in the nuclei as well as the cytoplasm in osteoclasts. The expression of β-catenin in osteoclast of CA-β-catenin mice was much higher than in the control (Fig. 1A-B) . To examine β-catenin expression patterns during the RANKL-mediated osteoclast differentiation process, mRNA expression levels of Trap (as a marker of osteoclast differentiation) and β-catenin were (Fig. 1E ). Trap and β-catenin expression levels increased gradually for 1-3 days in the presence of M-CSF and RANKL during osteoclastogenesis. Then, during the osteoclast maturation stage (days 4-6), the high expression levels of β-catenin were slightly downregulated. Consistently, Western blotting results showed that the expression of non-phosphorylated β-catenin increased during osteoclast differentiation ( Fig. 1F-H) . Non-phosphorylated β-catenin, which is translocated to the nucleus when cells receive canonical Wnt signalling, is the stabilized form of β-catenin [28, 29] . These findings implied that osteoclasts may be regulated by canonical Wnt signalling in osteoclastogenesis.
Ctsk-Cre site-specific expression was demonstrated in osteoclasts using reporter mice ( Fig. 2A-B) . Additionally, total and nuclear β-catenin expression increased in both long bones and in induced osteoclasts in vitro after β-catenin activation, indicating that β-catenin signalling increased in osteoclasts of CA-β-catenin mice (Fig. 2C-D) .
Developmental retardation and low bone mass in CA-β-catenin mice
After demonstrating β-catenin expression, we generated CA-β-catenin mice by intercrossing Ctnnb1 flox(exon3)/ flox(exon3) mice with Ctsk-Cre mice to achieve β-catenin stabilization in osteoclasts. CA-β-catenin mice displayed shorter and smaller body statures than their Control littermates (Fig. 3A ). There were no overt gender differences for this phenotype. Moreover, the weight of CA-β-catenin mice was also lower than that of Control mice (Fig. 3B) . Almost all the CA-β-catenin mice died at 6-7 weeks of age.
According to the micro-CT results, CA-β-catenin mice exhibited an obvious osteoporosis phenotype. Both three-dimensional reconstruction and coronal sections showed that the CA-β-catenin mice had shorter femurs and thinner cortical bones than the Control mice (Fig. 3C) . At the cross-section level, these phenotypes were further demonstrated by reconstruction of the trabecular bone of the distal femur and the cortical bone of the middle femur (Fig.  3D) . Quantitative morphometric analyses were consistent with low bone mass phenotypes, including the BV/TVs of cortical and trabecular bones, Tb.Th, Tb.Sp, Tb.N, and Ct.Th (Fig.  3E) . Detailed statistics are shown in Table 2 . Overall, these findings suggest that β-catenin stabilization in osteoclasts induces shorter stature and lower bone mass.
Histological loss of bone mass and increased osteoclasts in CA-β-catenin mice
In accordance with the micro-CT results, the histological staining analysis of CA-β-catenin mouse femurs showed severe loss of bone mass. There was a significant reduction in both the number of trabecular bones under growth plates and the thickness of the cortical bones (Fig. 4A) . Based on histochemical staining, bone mass loss (CA-β-catenin, 4 weeks old) was characterized by an increased number of TRAP-positive osteoclasts compared (Fig. 4B) . Quantitative statistical analysis of osteoclast numbers showed a 1.5-fold increase in TRAPpositive osteoclasts in CA-β-catenin mice (Fig. 4C) . The expression levels of osteoclastspecific genes were detected and compared to assess osteoclast functions in vivo. The expression levels of Trap, Nfatc1, Mmp9, Traf6, and Dcstamp were higher in the femurs from CA-β-catenin mice (Fig. 4D) . The expression levels of Wnt/β-catenin signalling-related genes, such as Tcf, Lef-1, Wisp and c-Myc, were significantly up-regulated in CA-β-catenin mice. These results suggested that increased osteoclast numbers due to activation of Wnt/β-catenin signalling play an important role in bone mass loss in CA-β-catenin mice.
Enhanced osteoclastogenesis in CA-β-catenin mice in vitro
To evaluate the function of β-catenin in the regulation of osteoclastogenesis, osteoclasts were induced from BMMs isolated from CA-β-catenin and Control mice in vitro. The number of osteoclasts was detected by TRAP staining (Fig. 5A, B and G) , CTSK expression (observed by immunofluorescence staining) (Fig. 5C, D and H) , actin ring formation (phalloidin labelling) (Fig. 5E, F and I ) and the expression of osteoclast-related genes (Fig. 5J) . Osteoclast differentiation and maturation were upregulated in CA-β-catenin mice, displayed greater numbers of TRAP-positive cells, CTSK-positive cells as well as more osteoclasts with actin ring (Fig. 5A-I) . Additionally, the expression of osteoclast-related markers and Wnt/β-catenin signalling-related main genes increased, including Trap, Nfatc1, Mmp9, Traf6, Ctr, Oscar, Dcstamp, Tcf, Lef-1, Wisp and c-Myc, which showed that osteoclast differentiation was enhanced in CA-β-catenin mice (Fig. 5J) . Therefore, these data demonstrated that constitutively activated β-catenin upregulates the osteoclastogenesis process in vitro. Expression of β-catenin in other organs in CA-β-catenin mice It has also been reported that CTSK can be expressed in other organs. Therefore, the expression of β-catenin was studied in several organs, including heart, liver, lung, kidney, brain and testis (Fig. 6) . The results showed that the expression of β-catenin was increased in liver in CA-β-catenin mice.
Discussion
The inhibition of osteoclast differentiation is an effective strategy to treat osteoporosis [30] . Thus, it is important to understand the mechanism underlying osteoclast formation. The Wnt/β-catenin pathway is essential for bone mass maintenance via the regulation of bone-forming osteoblasts [31] . However, the specific role of the Wnt/β-catenin pathway in osteoclast differentiation remains unclear. Hence, it is necessary to study the potential effects of the Wnt/β-catenin pathway on osteoclast-mediated bone resorption to provide a foundation for the treatment of osteoporosis. In this study, an in vivo mouse model was utilized to specifically activate β-catenin in osteoclasts. The results showed low bone mass in mice associated with enhanced osteoclast activity.
The specificity and validity of the mouse model is the basic principle. Theoretically, CTSK was predominantly thought to be unique to osteoclasts; however, it was also found in other organs [32, 33] . To confirm the specific expression of Ctsk-Cre mice, a dual-fluorescence gene-expression-reporter system and Western blotting analysis were applied and directly verified the site-specific expression pattern in osteoclasts. Moreover, the expression of β-catenin was also observed in several organs. According to our observations, though the expression of β-catenin in the liver increased, no obvious changes in the tissue structure and cell morphology were found. However, it does not rule out changes in liver function, which may result in systemic effects affecting bone. The possibility of systemic effects is a limitation of the present study.
In the present study, low bone mass was associated with enhanced osteoclast formation under β-catenin stabilization. β-catenin has been reported to upregulate RANKL through sclerostin to induce osteoclastogenesis processes [34] . Recently, c-Myc, a vital target of β-catenin, was demonstrated to mediate RANK/RANKL signalling in an NFATc1-dependent or NFATc1-independent manner. The c-Myc/ERRα pathway exerts significant effects on osteoclast energy metabolism, which is essential for bone resorption [35] [36] [37] . Consistently, the expression levels of c-Myc and molecules downstream of RANK/RANKL signalling increased in our study. Thus, β-catenin may regulate osteoclast differentiation via c-Myc and downstream signalling pathways. Moreover, the Wnt/β-catenin pathway acts as an upstream activator of the phosphatidylinositol 3-kinase/serine/threonine kinase (protein kinase B)/ 
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CA-β-catenin Control mammalian target of rapamycin (PI3K/Akt/mTOR) pathway, which is a critical RANK/ RANKL downstream signalling pathway [38] [39] [40] . However, the potential crosstalk between Wnt/β-catenin and other signalling pathways in osteoclastogenesis requires further studies. However, there are several findings regarding the effects of the Wnt/β-catenin signalling pathway on osteoclastogenesis. Loss-of-function or gain-of-function mutations in Lrp5, a Wnt/β-catenin signalling receptor, do not alter bone resorption [41] . The deletion of Sost or Dkk1, genes encoding inhibitors of the Wnt/β-catenin pathway, does not change osteoclast numbers [42] [43] [44] . Furthermore, studies have shown that β-catenin negatively regulates osteoclasts independent of osteoblasts [19] [20] [21] . Interestingly, our present work demonstrated that the activation of β-catenin in osteoclasts increased osteoclastic activity. We propose two possible reasons for this difference in osteoclastogenesis. On one hand, this contrast may be related to differences between in vivo and in vitro studies. In vivo studies may reflect a complex but real microenvironment, resulting in an integrated phenotype. On the other hand, the manipulation of GSK3β likely alters a variety of signalling pathways, which may explain these contradictory results. GSK3β is a component of many pathways, such as the Wnt and Hedgehog signalling pathways [45, 46] . GSK3β is also a key downstream effector of Akt pathway, which is required for osteoclast differentiation [47] . Moreover, mice overexpressing GSK3β driven by the TRAP promoter display osteopetrosis due to decreased osteoclast numbers [48] .
Wei and colleagues [18] reported that Ctsk-bCA mice exhibited an increased BV/TV ratio and decreased bone resorption by some statistical analysis, which was the opposite of our results. However, its detailed characterization, such as micro-CT analysis, histology analysis, and in vitro study, was quite limited. In this study, we validated the mouse model and performed morphological analyses on in vivo and in vitro osteoclast cultures. These data are presented objectively and systematically. Knockout of β-catenin in CTSK-expressing cells upregulates osteoclast-related gene expression and results in osteoporosis phenotypes [19] . Knockout or activation of β-catenin in bone-related cells, such as mesenchyme stem cells or osteoclast precursors, has similar phenotypes in bone [2, 18] . It is speculated that β-catenin exerts a biphasic regulation in osteoclastogenesis and leads to similar phenotypes. These similar phenotypes may be related to the complex and multidirectional effects of β-catenin, although the detailed mechanisms require further studies.
Unexpectedly, CA-β-catenin mice died early at 6-7 weeks of age. It is speculated that the early death of CA-β-catenin mice is partly due to severe osteoporosis and bone dysplasia, causing the abnormal development of other organs. On one hand, severe skeletal dysplasia leads to death. β-catenin is an important molecule and its dysfunction may lead to severe phenotypes in bone, which may be responsible for the death. Many studies have reported that deletion or constitutive activation of β-catenin in Cre-expression cells, such as Prx1-Cre, Osx1-Cre, Col1α1-Cre, OCN-Cre, Dmp1-Cre, Tie2-Cre and so on, causes early death in mice [2, 4, 5, 7, 8, 49, 50] . On the other hand, bone dysplasia, such as in the hypoplastic thorax, short limbs and ribs, causes damages to other organs and results in death [51, 52] . The exact reasons and mechanisms for this still require further investigation.
Our research found that β-catenin stabilization in osteoclasts might promote osteoclastogenesis. These findings are helpful for understanding the complex role of the Wnt/β-catenin signalling pathway in osteoclast differentiation and bone resorption. Moreover, this study may assist with the treatment of osteoporosis and other osteopenia diseases.
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